DefinePK

Abstract

Despite remarkable scientific advances in drug discovery, a persistent gap remains between pharmaceutical innovation and equitable access—particularly across emerging markets. This paper examines the structural and translational barriers that hinder the movement of therapeutics from the laboratory to patients who need them most. It introduces the concept of equitable commercialization, a framework that integrates translational science, market analytics, and policy design to align pharmaceutical innovation with public health equity. Using examples from diabetes and oncology therapies, the paper highlights how weak regulatory ecosystems, fragmented supply chains, and limited commercialization capacity continue to delay access to life-saving medicines in low- and middle-income countries. It further explores how data-driven approaches—such as predictive market analytics, adaptive regulatory frameworks, and university–industry partnerships—can serve as catalytic tools to bridge science and access. The proposed model emphasizes the moral and economic imperatives of equitable commercialization, calling for policies that incentivize innovation while ensuring affordability, local capacity building, and sustainable distribution. Ultimately, this work argues that transforming translational pathways through evidence-based commercialization strategies is essential to achieving global health equity and ensuring that scientific progress translates into measurable social good.
Keywords: Pharmaceutical Commercial Access, Emerging Market, Market Access.